Applied DNA Sciences, Inc. announced a strategic restructuring on June 30, 2025, which includes a 27% workforce reduction and the cessation of operations at its Applied DNA Clinical Labs to focus on its synthetic DNA business, LineaRx, while aiming for a 23% reduction in annual payroll costs, but will incur one-time charges of $300,000 related to these cuts.